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Paediatric antiretroviral treatment (ART) has improved survival 
in children living with perinatally acquired HIV (PHIV).[1] 
Consequently, an increasing number of girls, who were vertically 
infected by their mothers, are entering adolescence and adulthood, 
and are becoming pregnant. These young women have grown up 
with the effects of chronic HIV infection and long-term exposure 
to ART. They may also have increased psychosocial challenges, 
ART adherence difficulties and resistance mutations,[2-4] which may 
adversely affect their pregnancy outcomes. 
There are several published studies on the outcomes of pregnancies 
in youth living with PHIV (YLPHIV), but they are mostly from 
resource-rich settings: the USA,[5-16] the UK and Ireland[17-19] and 
other European countries.[20-22] Only a few studies are from resource-
limited settings, including Brazil,[23-25] Puerto Rico[26] and India.[27] 
Most studies are small: n<50 pregnant YLPHIV per study, except 
for 2 studies[5,6] that included 232 and 235 females, respectively. 
Some findings suggest that, in comparison with youth living with 
non-perinatally acquired HIV, those living with PHIV have higher 
rates of elective termination;[7,17] poorer immunological status 
during pregnancy;[5-7,10,11,14,15,17] poorer virological outcomes during 
pregnancy[5,6,8,14,15,17] and after pregnancy;[14] and are more likely to 
have drug resistance.[8,12] In some studies, infants born to mothers 
with PHIV had high rates of preterm birth[16] and, compared with 
infants of mothers with non-perinatally acquired HIV, higher mother-
to-child transmission (MTCT) of HIV,[5] lower birthweight[14,15] and 
birthweight-for-age,[11] and shorter stature at 12 months of age.[10] 
There is a lack of published data specifically addressing pregnancy 
outcomes in YLPHIV in sub-Saharan Africa, where >90% of the 
estimated 1.8 million children <15 years of age living with HIV reside.
[28] Over time, these children will enter childbearing age; therefore, 
the number of pregnancies emerging from this group is expected 
to increase. The lack of studies in sub-Saharan Africa may be due to 
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Background. An increasing number of girls living with perinatally acquired HIV (PHIV) are reaching adolescence and adulthood and 
becoming pregnant. Youth living with PHIV (YLPHIV) may have HIV-associated infections/complications, long-term exposure to 
antiretroviral treatment (ART), drug resistance and increased psychosocial challenges, which may adversely affect pregnancy outcomes. 
There is a lack of published studies on pregnancy in YLPHIV in sub-Saharan Africa. 
Objectives. To describe characteristics of pregnant South African (SA) YLPHIV and their pregnancy outcomes.
Methods. We retrospectively identified pregnancies in YLPHIV, who were diagnosed with HIV when they were <12 years old and before 
their first pregnancy (as a proxy for perinatal route of infection), from routinely collected data in Western Cape Province, SA (2007 - 2018). 
We combined these with pregnancies from a Johannesburg cohort of YLPHIV. 
Results. We identified 258 pregnancies among 232 females living with likely PHIV; 38.8% of pregnancies occurred in YLPHIV ≤16 years 
old, 39.1% at age 17 - 19 years and 22.1% at age ≥20 years. In recent years, a steady increase in the number of pregnancies in YLPHIV was 
noted; more than two-thirds occurred during 2016 - 2018. ART was commenced prior to pregnancy in 84.9% of YLPHIV, during pregnancy 
in 6.6% and was not commenced by pregnancy end date in 8.5%. Of the pregnancies in young women with documented outcomes (88.8%; 
n=229), 80.3% were live births, 14.4% terminations, 3.1% miscarriages and 2.2% stillbirths. Mother–to-child transmission of HIV occurred 
in 2.2% of infants, 75.3% were uninfected when last tested and 22.6% had unknown HIV status. Among YLPHIV with CD4 counts available 
within 12 months of pregnancy end date (n=202), 20.3% had a CD4 count <200 cells/µL, 43.1% CD4 count 200 - 499 cells/µL and 36.6% 
CD4 count ≥500 cells/µL. Among those with a viral load (VL) available within 12 months of pregnancy end date (n=219), 66.7% had a 
VL <400 copies/mL, 5.0% VL 400 - 999 copies/mL and 28.3% VL ≥1 000 copies/mL. Of 186 neonates, 20.4% were preterm deliveries 
(<37 weeks’ gestation). Among neonates with known birthweight (n=176), the mean birthweight was 2 900 g (95% confidence interval 
(CI) 2 747 - 2 935 g) and 20.5% had a low birthweight (<2 500 g). One congenital malformation (musculoskeletal) and 2 neonatal deaths were recorded. 
Conclusions. In recent years, the number of pregnancies in YLPHIV has increased. A considerable proportion of pregnancies occurred in 
YLPHIV ≤16 years old. A high proportion of pregnancies was electively terminated. The prevalence of elevated VL and poor immunological 
status among pregnant YLPHIV is concerning.
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several reasons, including limited capacity/resources for routine data 
collection. Less access to ART during earlier years of the epidemic may 
also have led to sub-Saharan African countries lagging behind many 
other countries, with few children surviving to reproductive age until 
relatively recently. Pregnant YLPHIV may be managed by services/
facilities (e.g. antenatal clinics) different to those where they receive 
their HIV care, resulting in pregnancy information not being captured 
with routine HIV program data. Furthermore, children, adolescents 
and adults are often seen together in integrated HIV clinics, which may 
make it less easy to monitor YLPHIV as a distinct group.
Our study is descriptive and aims to report the characteristics of 
pregnant YLPHIV in South Africa (SA) in terms of age; immunological 
and virological status; and ART in relation to pregnancy. We describe 
pregnancy outcomes in terms of live births, stillbirths, miscarriages 
and termination of births; and neonatal outcomes in terms of MTCT, 
congenital abnormalities, deaths, preterm deliveries and birthweight.
Methods 
The International epidemiologic Databases to Evaluate AIDS 
Southern Africa collaboration (IeDEA-SA) undertakes research to 
improve the long-term delivery of HIV care and ART services. The 
combined database includes individual-level data from several large 
collaborating cohorts in Malawi, Zambia, SA, Mozambique, Lesotho 
and Zimbabwe. All IeDEA-SA sites were invited to contribute data 
to this analysis. However, most sites, except those in Western Cape 
Province of SA and one in Johannesburg, did not have routinely 
collected data on pregnancies.
The Western Cape Department of Health has a variety of electronic 
record systems for routine delivery of healthcare, including the 
management of hospital and primary care administration, drug 
dispensing and laboratory records. Patient records are linked across 
systems through a unique patient identifier. The integration of this 
data is managed by the Provincial Health Data Centre (PHDC), 
which provided the Western Cape data for this analysis.[29] We used 
routinely collected data from the Western Cape PHDC between 2007 
and 2018. The data were received late in 2018; therefore, the 2018 
data were not complete.
Pregnancy in women is provisionally identified by the PHDC 
if there is a rhesus antibody test, midwife obstetric unit visit, 
International Classification of Diseases 10th Revision (ICD-10) code 
indicating a pregnancy or pregnancy outcome, drugs dispensed for 
the termination of pregnancy, or a birth recorded on the birth register. 
Based on these integrated data, a pregnancy outcome and outcome 
date are inferred for each woman. If additional data are available, 
the outcome date is inferred by using the last menstrual period 
date, delivery date or gestational age. If no outcome is recorded, the 
pregnancy end date is predicted to be 41 weeks after the first evidence 
of pregnancy. Pregnancy confidence scores are calculated by the 
PHDC to measure the degree of confidence that the data sources used 
for inferring pregnancy truly indicate a pregnancy. We restricted our 
analysis to women with a pregnancy confidence score ≥0.7 (‘probable 
pregnancies’), with outcome dates between 1 January 2007 and 31 
December 2018. As the mode of HIV transmission is not routinely 
collected, we identified pregnancies in those who received HIV care 
before the age of 12 years and before the first pregnancy, as a proxy 
for perinatal route of infection. 
We combined pregnancy data from the Western Cape with those 
from a smaller cohort of adolescents with PHIV from Rahima Moosa 
Hospital in Johannesburg, SA, from the same time period (2007 - 
2018). Rahima Moosa Hospital has a paediatric and adolescent HIV 
clinic that currently includes ~1 600 patients, of whom ~1 000 are 
adolescents. Information on mode of HIV transmission, pregnancy 
and pregnancy outcomes is collected routinely in the clinic and 
recorded in patient files and on the electronic database. Proxies and 
confidence scores were not applied, as the Johannesburg data were 
recorded directly from patient files; hence, there is 100% certainty 
about those pregnancies.
The observed age distribution of pregnant YLPHIV was compared 
with that of female YLPHIV in the Western Cape in 2016, as 
estimated by the Thembisa model (version 4.2).[30] Thembisa is a 
combined demographic and HIV model that has been developed 
for SA and applied to each province, and is the main source of 
Joint United Nations Programme on HIV and AIDS (UNAIDS) 
estimates for SA. The model estimate of YLPHIV was obtained by 
taking estimated numbers of people living with HIV at each age 
and subtracting the numbers that would have been predicted by the 
model if there was no MTCT.
After combining the Western Cape and Johannesburg data, CD4 
counts of the young women were recorded as the result closest to 
pregnancy end date, within 12 months before or after pregnancy 
end date. Viral load (VL) was also recorded as the result closest to 
pregnancy end date, within 12 months before or after pregnancy 
end date. Furthermore, among pregnancies with an outcome of live 
birth, the VL measurement during pregnancy and nearest to delivery 
date was recorded (within 41 weeks before delivery or 7 days after 
delivery) and compared with the first VL available postpartum 
(measured >7 days post-delivery date and within 12 months of 
delivery date). Preterm births were defined as those occurring at 
<37 weeks’ gestation. Low birthweight was defined as <2 500 g.
Ethical approval
Analysis of the Western Cape data was undertaken as part of a 
broader evaluation of the impact of expanded access to ART in 
pregnancy, approved by the Human Research Ethics Committee at 
the University of Cape Town (ref. no. UCT HREC 541/2015). The 
contributions made by the Johannesburg site were approved by the 
University of the Witwatersrand Human Research Ethics Committee 
(ref. no. M170788), which includes approval to share anonymised 
data with the IeDEA Data Centre at UCT for analysis. The IeDEA 
Data Centre has approval for the analysis of anonymous data from 
any IeDEA-SA collaboration site (ref. no. HREC 084/2006). Data 
were collected through routine health services and were anonymised 
before data sharing with the researchers.
Results 
Of 804 495 pregnancies recorded from Western Cape health 
facilities between 2007 and 2018, 163 351 (20.3%) had evidence 
of maternal HIV. Of these, 228 had evidence of maternal HIV 
before age 12 years and before the estimated start date of the first 
pregnancy. Data were also provided from Rahima Moosa Hospital 
on 30 pregnancies among adolescents known with PHIV. In total, 
258 pregnancies among 232 adolescents and women living with 
likely PHIV were identified.
Outcomes were documented in 88.8% of pregnancies (n/N=229/258). 
Among these, 80.3% (n=184) resulted in live births (including 
2 sets of twins), 14.4% (n=33) elective terminations, 3.1% (n=7) 
miscarriages and 2.2% (n=5) stillbirths. 
The number of YLPHIV with pregnancies increased annually 
(Fig. 1), with 67.4% during 2016 - 2018. The proportion of pregnancies 
in YLPHIV >16 years of age increased annually. Age at the start of 
pregnancy ranged from 10 to 24 years (Fig. 2); 46.1% of pregnancies 
occurred in those aged ≤16 years, 32.6% at 17 - 19 years of age, 
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while 21.3% were in adults ≥20 years old. 
Moreover, the changing age distribution of 
YLPHIV is demonstrated in Fig. 2, which 
shows estimates of the age distribution of 
females (aged 10 - 25 years) living with 
PHIV in the the Western Cape in 2016. 
For 232 women, we recorded a single 
pregnancy, for 21 women, 2 pregnancies 
and for 5 women, 3 pregnancies. ART was 
commenced before pregnancy in 84.9% of 
cases, during pregnancy in 6.6% and not 
commenced by pregnancy end date in 8.5%. 
In pregnant women with CD4 counts 
available within 12 months of pregnancy 
end date (n/N=202/258; 78.3%), 20.3% 
had severe immunosuppression, with a 
CD4 count <200 cells/µL, 21.3% CD4 
count 200 - 349 cells/µL, 21.8% CD4 
count 350 - 499 cells/µL and 36.6% had 
optimal immuno logical status (≥500 cells/µL) 
(Fig. 3A). Median time between pregnancy end 
date and CD4 count was 104 (interquartile 
range (IQR) 51 - 173) days. Among those 
with VL available within 12 months 
of pregnancy end date (n/N=219/258; 
84.9%), 66.7% had a VL <400 copies/mL, 
5.0% VL 400 - 999 copies/mL and 28.3% 
VL ≥1 000 copies/mL (Fig. 3B). Median 
time between pregnancy end date and VL 
was 36 (IQR 11 - 84) days.
Among the subset of pregnancies in women 
who had live birth outcomes, VL during 
pregnancy was compared with VL postpartum. 
Of those with VL available during pregnancy 
(n/N=143/184; 77.7%), 66.4% had a VL <400 
copies/mL, 5.6% VL 400 - 999 copies/mL and 
28.0% VL ≥1 000 copies/mL. Among those 
with VL available postpartum (n/N=90/184; 
48.9%), 60.0% had a VL <400 copies/mL, 
10.0% VL 400 - 999 copies/mL and 30.0% VL 
≥1 000 copies/mL. For women with pregnancies 
that ended in 2018, the data were incomplete 
for the postpartum period, resulting in many 
unknown postpartum VL values. After 
excluding the pregnancies from 2018, among 
the subset of pregnant women who had live 
birth outcomes and VL available during 
pregnancy (n/N=101/139; 72.7%), 68.3% 
had a VL <400 copies/mL, 5.9% VL 400 - 999 
copies/mL and 25.7 % VL ≥1 000 copies/mL. 
Among those with VL available postpartum 
(n/N=86/139; 61.9%), 61.6% had a VL <400 
copies/mL, 10.5% VL 400 - 999 copies/mL 
and 27.9% VL ≥1 000 copies/mL. Mc Nemar’s 
χ2 test showed that there was a statistically 
significant decrease in the proportion with VL 
measurements available postpartum v. during 
pregnancy (38.1% v. 27.3%; p=0.03).
Among the 186 live births, MTCT of 
HIV occurred in 2.2% of infants (n=4), 
75.3% were uninfected when last tested 
and in 22.6% HIV status was unknown. 
Mothers who transmitted HIV to their 
infants were young (age 13, 15, 16 and 16 years 
at conception). One of the mothers had an 
undetectable VL before delivery (measured 
2 months prior to delivery). Two of the 
other mothers had a raised VL at delivery 
(>1 000 copies/mL), whereas the remaining 
mother did not have VL monitoring during 
pregnancy (although VL prior to pregnancy 
was >1 000 copies/mL). There were 2 neonatal 
deaths and 1 congenital abnormality, which 
was described as a proximal focal femoral 
deficiency. Of the pregnancies that resulted 
in live births, 20.4% were preterm deliveries. 
Among neonates with known birthweights 
(n/N=176/186), the mean birthweight was 
2 900 g (95% confidence interval (CI) 2 747 - 
2  935 g) and 20.5% of neonates had a low 
birthweight (<2 500 g).
Discussion
In recent years, there has been a striking 
increase in pregnancies among YLPHIV; 
over two-thirds occurred during the 
past 3 years, with a large proportion in 
adolescents aged ≤16 years. Concerningly, 
in one-third of pregnancies, YLPHIV had 
elevated VLs (≥400 copies/mL) and in one-fifth 
of pregnancies, YLPHIV had severe immuno-
suppression (CD4 count <200 cells/µL). The 
age distribution of these pregnant young 
women, who included many adolescents 
aged ≤16 years, reflects the current context 
of YLPHIV in the Western Cape, where 
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Fig. 2. Number of pregnancies by age, depicted alongside Thembisa model estimates, showing the age 
distribution of females living with perinatally acquired HIV (PHIV) (age 10 - 25 years) in Western Cape 
Province, South Africa, in 2016.
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age category, with relatively few in the older 
age categories. Fig. 2 demonstrates how 
the age distribution of pregnant YLPHIV 
mirrors the estimates of the age distribution 
of females living with PHIV in the Western 
Cape in 2016, whereas Fig. 1 shows that the 
proportion of pregnancies among YLPHIV 
>16 years of age has increased annually, as 
the YLPHIV cohort has grown older. 
A high proportion of YLPHIV electively 
terminated their pregnancies (14.4%), 
suggesting reasonable access to this service, 
although this also implies that rates of 
unintended pregnancy are high and 
suggests poor access to or poor uptake of 
contraception. Because routine data from 
health services were used to assess whether 
pregnancies were terminated, it is likely 
to be fairly representative of terminations 
in the public health service as opposed 
to self-reported outcomes, which are more 
prone to bias. The majority of pregnancies 
occurred in adolescents. Although this most 
likely reflects the current age distribution 
of SA’s YLPHIV population, it is evident 
that many YLPHIV become sexually active 
while still under the care of paediatric HIV 
services, where provision of integrated 
family planning services may not be well 
provided. There may be a need to provide 
more proactive sexual and reproductive 
health services and counselling to these 
youth. Earlier referral of young people to 
adolescent/youth services or differential care 
models to increase access to contraceptives 
may be preferable to keeping adolescents/
youth in paediatric care models where this 
may be poorly implemented.
The high proportion of pregnant YLPHIV 
who had elevated VLs (≥400 copies/mL) 
or severe immunosuppression (CD4 
count <200 cells/µL) is a concern, as it can 
be anticipated that in the years to come, 
an increasing number of pregnancies will 
occur among women living with PHIV, who 
may have similar poor virological and/or 
immunological status. Elevated maternal VL 
places infants at higher risk of MTCT, where-
as severe maternal immunosuppression 
places mothers at higher risk of opportunistic 
infections and/or death, which in turn is a 
risk for poor infant outcomes. 
A small study of long-term retention in 
care and viral suppression in postpartum 
women with PHIV,[9] as well as a systematic 
review and meta-analysis to estimate 
ART adherence rates during pregnancy 
and postpartum (not specifically PHIV 
women),[31] has demonstrated significant 
decreases in postpartum ART adherence. In 
our cohort, among pregnancies that resulted 
in live births, a decrease was observed in the 
proportion of YLPHIV known to be virally 
suppressed postpartum (61.6% v. 68.3% 
during pregnancy). However, there was a 
significantly higher proportion of YLPHIV 
with unknown postpartum VL (38.1% 
v. 27.3% during pregnancy), which makes 
interpretation of these findings difficult. 
Programmatically, it can be anticipated that 
women receiving ART should have annual 
VL monitoring; therefore, it may be that 
many of those without postpartum VL 
dropped out of care and were not virally 
suppressed. It may also be that less attention 
is paid to VL monitoring in the postpartum 
period. Poor monitoring of VL postpartum 
is concerning, especially as breastfeeding is 
generally promoted. Adolescents are typically 
transitioned to adult care when pregnant, 
and if the transition is to a less supportive 
environment, it may influence adherence.
MTCT of HIV is known to have occurred 
in 2.2% of neonates, comparable to a reported 
national early MTCT rate of 2.4%,[32] although 
22.6% of the exposed infants in this cohort 
had not been tested for HIV, and additional 
transmissions from breastfeeding may have 
subsequently occurred among the infants who 
initially tested negative.
Study limitations
Limitations for this study include that the 
Western Cape data were received late in 2018; 
therefore the 2018 data were incomplete and 
the total number of pregnancies for 2018 is 
likely to be higher than the number reported.
Pregnancies prior to 2007 were not included; 
therefore, it is likely that the total YLPHIV 
pregnancies are under-estimated. Pregnancy 
and outcome data were not collected directly 
from young women in the Western Cape and 
were inferred in some cases; consequently, 
there may be missing/incomplete/inaccurate 
data. Moreover, we used strict criteria to 
identify pregnancy in the Western Cape 
dataset (confidence score ≥0.7), resulting in 
many ‘possible pregnancies’ being excluded. 
A further limitation was that we did not have 
a comparison group of women with non-
perinatally acquired HIV; therefore, the study 
is purely descriptive. Survival bias is present 
for those who are well enough to age into 
adolescence, with child-bearing potential.
The prevalence of preterm birth and low 
birthweight in women living with HIV in SA 
is not known. A large prospective study of a 
Cape Town cohort from a community-based 
primary care clinic (not disaggregated by 
mode of infection) found that, among women 
with HIV, preterm deliveries occurred in 
22% of cases and low birthweight among 
14% of neonates.[33] However, a large cohort 
study from rural KwaZulu-Natal found that, 
among neonates born to women with HIV, 
10.4% were born prematurely and 9.6% had 
a low birthweight.[34] In our YLPHIV cohort, 
20.4% of births were preterm deliveries and 
20.5% of neonates had a low birthweight. 
In addition to the effects of chronic HIV 
infection and long-term exposure to ART, 
because they are mostly still adolescents and 
young adults, YLPHIV may typically be at 
higher risk of pregnancy complications such 
as preterm delivery and low birthweight.
Studies comparing pregnancies in women 
with PHIV and women with non-perinatally 
acquired HIV in SA are needed to assess 
whether these outcomes differ.
Conclusions
Albeit a largely descriptive study, this is one 
of the first studies on pregnancy outcomes 
in YLPHIV in sub-Saharan Africa. The 
next step should be a comparison with 
pregnancies in women in resource-limited 
settings who have non-perinatally acquired 
HIV to assess whether the perinatally 
acquired group is at risk of worse outcomes.
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Fig. 3. Proportion of pregnancies with: (A) different CD4 count (cells/µL) categories; and (B) different 
viral load (copies/mL) categories.
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